October 3, 2025 — Leads & Copy — Kahn Swick & Foti, LLC (“KSF”) is investigating the proposed merger of Barinthus Biotherapeutics plc (NasdaqGM: BRNS) and Clywedog Therapeutics, Inc. Under the terms, Barinthus shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share owned, and Clywedog shareholders will receive 4.358932 shares of common stock in the new combined company for each common or preferred share owned.
KSF seeks to determine whether the merger and the process are adequate and fair to Barinthus shareholders.
Those wishing to discuss their legal rights may email KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) or call toll free at 855-768-1857, without obligation or cost or visit https://www.ksfcounsel.com/cases/nasdaqgm-brns/ to learn more.
Contact:
Lewis S. Kahn (lewis.kahn@ksfcounsel.com) 855-768-1857
Source: KSF Law
